Court victory paves the way for Curium's plans to provide targeted radioligand therapy to U.S. patients with GEP-NETs
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- Curium is pleased to announce that it has prevailed in the patent dispute brought by Novartis subsidiary A
